Include All CSL Behring Country Sites


Media Contacts:


Sharon McHale
Mobile: +44 (0) 7810 757030

United States

David Minella
Mobile: +1 919 802 7641

Asia Pacific

Melanie Kerin
Mobile: +61 (0) 417 436 329

News Releases

Seqirus announces major advances in pandemic preparedness
Seqirus, a global leader in the prevention of influenza, announced today that the accelerated development of cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats. More.

Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. More.

Seqirus announces next major advancement in cell-based influenza vaccine technology
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at the state-of-the art manufacturing facility in Holly Springs, North Carolina. More.

Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older. AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), are available in the US for the 2016-2017 influenza season. More.

Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children
Seqirus today announced results of two data integrated analyses from six randomized clinical trials evaluating the safety and immunogenicity of its trivalent MF59-adjuvanted seasonal influenza vaccine in children aged six months to less than six years. 1,2 More.

Joint media release from Invest Liverpool, the Mayor of Liverpool and Seqirus

Today the world’s no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. More.